Pauls Dietrich John 4

What Happened Pauls Dietrich John, President & CEO and a director of DiaMedica Therapeutics, was granted 380,000 derivative shares on June 1, 2026. The filing shows an acquisition at $0.00 per share (total reported value $0), recorded as an award/grant (transaction code A).

Key Details

• Transaction date: 2026-06-01; Form 4 filed: 2026-06-03 (timely within the standard reporting window).
• Grant: 380,000 derivative shares, price reported $0.00 (no cash paid at grant).
• Vesting (footnote F1): 25% vests on the one-year anniversary of the grant date; the remaining 75% vests in twelve equal quarterly installments thereafter (i.e., typical 4-year-style schedule with a one-year cliff).
• Shares owned after the transaction: not specified in the provided filing summary.
• Transaction code: A = Award/Grant (derivative securities).

Context This filing reflects a compensation-related equity award rather than an open-market purchase or sale. Such grants are commonly used to align executive incentives with shareholder value; they do not by themselves indicate buying or selling activity. Because this is a derivative award with a vesting schedule, the shares are not all immediately transferable or taxable at grant (vesting and tax treatment depend on plan terms and elections).